docetaxel anhydrous has been researched along with gossypol acetic acid in 10 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (gossypol acetic acid) | Trials (gossypol acetic acid) | Recent Studies (post-2010) (gossypol acetic acid) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 209 | 16 | 77 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | gossypol acetic acid (IC50) |
|---|---|---|---|
| Mcl-1 | Homo sapiens (human) | 1.2628 | |
| Valosin-containing protein | Homo sapiens (human) | 5.386 | |
| Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 1.17 | |
| Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 1.17 | |
| Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 1.17 | |
| Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 1.17 | |
| 60 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 1.2 | |
| Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 1.17 | |
| 10 kDa heat shock protein, mitochondrial | Homo sapiens (human) | 1.2 | |
| 60 kDa chaperonin | Escherichia coli | 0.545 | |
| 10 kDa chaperonin | Escherichia coli | 0.545 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA | 1 |
| Armstrong, AJ; Berry, WR; Brookes, M; de Wit, R; Eisenberger, MA; Leopold, L; Pond, GR; Sonpavde, G; Tannock, IF; Wood, BA | 1 |
| Shen, Y; Ye, D | 1 |
| Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA | 1 |
| Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z | 1 |
| Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA | 1 |
| Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP | 1 |
| Ajani, JA; Bhutani, M; Chen, Q; Correa, A; Estrella, JS; Gan, B; Hofstetter, WL; Huo, L; Jin, J; Johnson, RL; Lee, JH; Lei, G; Li, CY; Li, Y; Liu, B; Ma, L; Pizzi, MP; Scott, A; Shanbhag, N; Song, S; Wang, Y; Wei, S; Weston, B; Xiao, L | 1 |
7 trial(s) available for docetaxel anhydrous and gossypol acetic acid
| Article | Year |
|---|---|
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Taxoids | 2011 |
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Treatment Outcome | 2012 |
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Prednisone; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids | 2013 |
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neutropenia; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2012 |
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors | 2014 |
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gossypol; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2016 |
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Female; Gossypol; Humans; Male; Mice; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2021 |
3 other study(ies) available for docetaxel anhydrous and gossypol acetic acid
| Article | Year |
|---|---|
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Gossypol; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Gossypol; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids | 2012 |
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cells, Cultured; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gossypol; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neovascularization, Physiologic; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |